ReviewCellular & molecular biology letters2021

Targeting the GPR119/incretin axis: a promising new therapy for metabolic-associated fatty liver disease.

Jianan Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.